Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics VKTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 53% leaning bullish and 33% bearish. Among these notable options, 4 are puts, totaling $177,403, and 11 are calls, amounting to $454,376.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $100.0 for Viking Therapeutics during the past quarter.
Volume & Open Interest Development
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Viking Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Viking Therapeutics's significant trades, within a strike price range of $55.0 to $100.0, over the past month.
Viking Therapeutics Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | SWEEP | BULLISH | 05/17/24 | $5.9 | $5.6 | $5.9 | $65.00 | $93.8K | 2.7K | 203 |
| VKTX | PUT | TRADE | BEARISH | 06/21/24 | $13.1 | $12.7 | $13.0 | $70.00 | $83.2K | 165 | 150 |
| VKTX | CALL | SWEEP | BEARISH | 04/26/24 | $1.4 | $1.1 | $1.1 | $71.00 | $48.8K | 101 | 458 |
| VKTX | CALL | TRADE | BULLISH | 06/21/24 | $9.4 | $9.0 | $9.3 | $65.00 | $46.5K | 184 | 24 |
| VKTX | CALL | TRADE | BEARISH | 05/17/24 | $6.1 | $5.7 | $5.82 | $65.00 | $43.6K | 2.7K | 279 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Where Is Viking Therapeutics Standing Right Now?
- With a volume of 1,085,399, the price of VKTX is up 1.53% at $64.39.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 2 days.
What The Experts Say On Viking Therapeutics
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $122.75.
- Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $90.
- Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Viking Therapeutics, targeting a price of $138.
- Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Viking Therapeutics with a target price of $125.
- An analyst from Oppenheimer has decided to maintain their Outperform rating on Viking Therapeutics, which currently sits at a price target of $138.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
